Back to top
more

VanEck Biotech ETF: (BBH)

(Delayed Data from NASDAQ) As of Jul 5, 2024 03:59 PM ET

$168.16 USD

168.16
7,246

+1.10 (0.66%)

Volume: 7,246

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $168.24 +0.08 (0.05 %) 7:58 PM ET

Zacks News

Sweta Jaiswal, FRM headshot

Why Biotech ETFs Surged in Monday's Trading Session

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Sweta Killa headshot

Biotech ETF (BBH) Hits New 52-Week High

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Sanghamitra Saha headshot

Risk-On Sentiments Are Back: ETFs to Play

The global market has been rallying hard since October. Investors can thus bet on these high-flying ETFs.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q3 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q3 earnings results recently.

Sanghamitra Saha headshot

Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

Sweta Jaiswal, FRM headshot

Top-Performing Biotech ETFs YTD

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.

Sweta Killa headshot

Amgen to Buy Celgene's Otezla: 5 ETF Drugs

Amgen agreed to buy psoriasis and psoriatic arthritis drug Otezla from Celgene for $13.4 billion in cash.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on Impressive Q2 Earnings Results

Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.

Sweta Killa headshot

AbbVie to Buy Allergan: Prescribed ETFs

AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on String of Q1 Earnings Beats

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

Sweta Jaiswal, FRM headshot

Will Biotech ETFs Continue to Rally in Q1 Earnings?

Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .

Sanghamitra Saha headshot

Health Day Checkup of Medical ETFs: 5 Top Picks

M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.

Sweta Killa headshot

Top-Ranked ETF Winners in Dow's Longest Rally in 24 Years

While there are winners in many corners of the space, some ETFs have crushed the Dow Jones by wide margins in three months.

Sanghamitra Saha headshot

Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.

Sweta Killa headshot

Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.

Biotech ETFs in Focus on String of Q3 Earnings Beat

Biotech ETFs draw attention post impressive Q3 results.

Sanghamitra Saha headshot

Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.

    Sweta Killa headshot

    Biotech ETFs Surge on Biogen's Positive Drug Trial Result

    Biotech ETFs surge on Biogen's encouraging Phase 2 clinical study data for Alzheimer???s treatment.

      Sanghamitra Saha headshot

      Top-Ranked Sector ETFs to Buy for Q3

      These sector ETFs have a Zacks Rank #1 or 2 and are likely to outperform ahead.

        Sweta Killa headshot

        How to Build a Winning ETF Portfolio Amid Trade War Fears

        We have highlighted some strategies that could prove extremely beneficial for investors in a choppy market.

          3 ETFs to Watch on Biotech Earnings

          Major Biotech companies report mixed Q4 results.

            3 ETFs to Watch on Biotech Earnings

            Major Biotech companies report mixed Q3 results.

              3 ETFs to Watch Out for on Biotech Earnings

              Major players in the biotech space reported their second quarter 2017 results.

                Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus

                Gilead beat Zacks EPS estimates, but missed on revenue, in the first quarter of 2017.